- Home
- PRAX vs JFR Comparison
PRAX vs JFR Comparison
Compare PRAX & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- JFR
- Stock Information
- Founded
- PRAX 2015
- JFR 2004
- Country
- PRAX United States
- JFR United States
- Employees
- PRAX N/A
- JFR N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- PRAX Health Care
- JFR Finance
- Exchange
- PRAX Nasdaq
- JFR Nasdaq
- Market Cap
- PRAX 950.8M
- JFR 1.1B
- IPO Year
- PRAX 2020
- JFR N/A
- Fundamental
- Price
- PRAX $46.85
- JFR $8.43
- Analyst Decision
- PRAX Strong Buy
- JFR
- Analyst Count
- PRAX 9
- JFR 0
- Target Price
- PRAX $94.44
- JFR N/A
- AVG Volume (30 Days)
- PRAX 388.4K
- JFR 621.7K
- Earning Date
- PRAX 08-04-2025
- JFR 01-01-0001
- Dividend Yield
- PRAX N/A
- JFR 11.31%
- EPS Growth
- PRAX N/A
- JFR N/A
- EPS
- PRAX N/A
- JFR N/A
- Revenue
- PRAX $7,765,000.00
- JFR N/A
- Revenue This Year
- PRAX N/A
- JFR N/A
- Revenue Next Year
- PRAX $25.00
- JFR N/A
- P/E Ratio
- PRAX N/A
- JFR N/A
- Revenue Growth
- PRAX 338.45
- JFR N/A
- 52 Week Low
- PRAX $26.70
- JFR $7.61
- 52 Week High
- PRAX $91.83
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- PRAX 47.63
- JFR 47.58
- Support Level
- PRAX $44.13
- JFR $8.38
- Resistance Level
- PRAX $47.06
- JFR $8.53
- Average True Range (ATR)
- PRAX 2.18
- JFR 0.05
- MACD
- PRAX 0.05
- JFR 0.00
- Stochastic Oscillator
- PRAX 54.73
- JFR 80.00
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.